Found 30 Dementia trials
A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Featured study
The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the …
Featured study
Test Trial - v7.0What is the purpose of this study?This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with …
Featured study
Featured study
The research study is being conducted to learn about the work of breathing support that an external breathing support device can provide compared to a person’s baseline ability. The research study is sponsored by RightAir Inc, the makers of the device being investigated, the AIR-AD cuirass ventilator. This study is …
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
The purpose of this study is to develop a large, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials. Will utilize feeder registries as well as participants with known biomarker status. Enrollment into TRC involves in-clinic evaluation and biomarker confirmation, with additional visits every 6 months. This may …
The aim of the Alzheimers Disease Neuroimaging Initiative (ADNI) has been to validate biomarkers for Alzheimers disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic …
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D.. We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data and biological samples, …
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
Please choose between Voice or SMS based delivery of verification code
or